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Abstract Gels are one of the soft material platforms being
evaluated to deliver topically acting anti-HIV drugs
(microbicides) to the vaginal environment. For each drug, its
loaded concentration, gel properties and applied volume, and
frequency of dosing can be designed to optimize PK and,
thence, PD. These factors also impact user sensory percep-
tions and acceptability. Deterministic compartmental model-
ing of vaginal deployment and drug delivery achieved by test
gels can help delineate how multiple parameters characteriz-
ing drug, vehicle, vaginal environment, and dosing govern
details of PK and PD and also gel leakage from the canal.
Such microbicide delivery is a transport process combining
convection, e.g., from gel spreading along the vaginal canal,
with drug diffusion in multiple compartments, including gel,
mucosal epithelium, and stroma. The present work builds up-
on prior models of gel coating flows and drug diffusion (with-
out convection) in the vaginal environment. It combines and
extends these initial approaches in several key ways, includ-
ing: (1) linking convective drug transport due to gel spreading
with drug diffusion and (2) accounting for natural variations in
dimensions of the canal and the site of gel placement therein.
Results are obtained for a leading microbicide drug, tenofovir,
delivered by three prototype microbicide gels, with a range of
rheological properties. Themodel includes phosphorylation of
tenofovir to tenofovir diphosphate (which manifests reverse
transcriptase activity in host cells), the stromal concentration
distributions of which are related to reference prophylactic
values against HIV. This yields a computed summary measure
related to gel protection (Bpercent protected^). Analyses illus-
trate tradeoffs amongst gel properties, drug loading, volume
and site of placement, and vaginal dimensions, in the time and
space history of gel distribution and tenofovir transport to sites
of its anti-HIVaction and concentrations and potential prophy-
lactic actions of tenofovir diphosphate therein.
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Introduction
Products for delivery of topically acting anti-HIV drugs
(microbicides) are important alternatives to vaccines in pre-
vention strategies against sexually transmitted HIV. Both the
vaginal and rectal environments are being targeted [1–3].
Multiple microbicide drugs are being evaluated and are for-
mulated in several types of vaginal delivery systems, includ-
ing gels, rings, films, woven fiber meshes, and foaming tablets
[2, 4–7]. These drugs act against HIV by several mechanisms
of action within vaginal fluids and/or the mucosal tissue that
contains host cells which sexually transmitted HIV can infect.
Clearly, the mission of a microbicide product is to establish
concentration distributions, in time and space, of its active
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drug(s) in target fluids and/or tissues, which are sufficient to
prevent infection.
Vaginal gels have received much attention as microbicide
delivery systems. However, no gel, to date, has successfully
completed phase 3 trials. Most recently, a gel containing the
antiretroviral drug tenofovir showed efficacy in its first phase
3 trial (CAPRISA 004) but failed in its second and third trials
(VOICE, FACTS) [8–10]. The latter two failures have been
attributed in large part to very poor trial participant adherence
to specified gel dosage regimen. Clearly, microbicide gel suc-
cess derives from synergy of efficacious pharmacokinetics
(PK) and pharmacodynamics (PD) as linked to adequate will-
ingness to use. The CAPRISA 004 trial showed that these
could be achieved for the tenofovir gel loaded with 1 % drug
and applied in a 4-mL volume in a before-and-after-sex
(BAT24) regimen. Results from subsets of participants in the
VOICE and FACTS trials who did consistently use the gel
also suggested moderate efficacy. However, the VOICE and
FACTS trials showed that adequate willingness to use was not
achieved for this gel-volume combination, either in once daily
(VOICE) or on-demand BAT24 (FACTS) dosing.
Microbicide PK derives from the interaction of gel spread-
ing along the vaginal canal and drug transport out from the gel
and into ambient fluid(s) and the layers of the vaginal mucosa.
Gel spreading and drug mass transport relate to drug proper-
ties and loading, gel properties and volume, frequency of gel
application, and properties of the host environment, including
sexual activity and semen [3]. Willingness to use derives in
part from user sensory perceptions and preferences of a gel in
relation to its dosage regimen. Those perceptions relate in part
to gel spreading along the vaginal canal and leakage there-
from, which derive from properties of the gel and its applied
volume [11, 12]. Thus, there is an overlap in the influence of
gel spreading and thus gel properties and volume upon phar-
macological prophylactic efficacy and behavioral willingness
to use. Deterministic modeling of gel deployment and drug
delivery is a scientific tool that can help understand the deter-
minants of both the PK and user willingness to use. Such
modeling can thus contribute to objective design of microbi-
cide gels that succeed both pharmacologically and
behaviorally.
Tenofovir (TFV) exhibits its anti-HIV function (reverse
transcriptase inhibition) after entering HIV-infectible host
cells and becoming phosphorylated to tenofovir diphosphate
(TFV-DP). The lower of the two vaginal mucosal layers, the
stroma, contains a population of these cells and is believed to
be a primary site of infection by vaginally transmitted HIV.
Contemporary pharmacokinetic modeling of microbicide
drug products (e.g., population PK models) has utilized em-
pirical approaches in which each compartment is homoge-
neous, and the drug transport process is highly simplified to
first-order exchange between compartments [13]. These ap-
proaches are quite valuable to our understanding of whole
body microbicide PK and are helping quantify sources of var-
iability in it. However, by nature, they do not capture all phys-
ical and physicochemical mechanisms that drive drug mass
transport. Such transport is governed by convection and dif-
fusion processes, which depend upon rates of gel spreading
and concentration gradients within compartments.
Consequently, the empirical models cannot objectively ac-
count for the non-linear multiparametric dependence of drug
concentration distributions upon characteristics of product, its
dosing, and host environment nor can they characterize spatial
concentration distributions of drugs within compartments
(which can be quite non-uniform [14], see below). The present
study builds upon earlier modeling work by our group in
initiating creation and application of a deterministic method-
ology to contribute to understanding the determinants of the
drug transport process. In doing so, we apply a modeling
approach that has been developed and proven beneficial in
many other drug delivery contexts, e.g., transdermal delivery
[15, 16].
Drug release from a gel into the vaginal mucosa occurs
over the contact (coating) area of gel and epithelial surface.
Drug is also released from gel into ambient vaginal fluids and,
subsequently, may enter the mucosa. The gel-mucosal contact
surface grows over time after gel insertion. Initial analyses of
the mechanisms of microbicide gel drug delivery performance
drew inferences from gel spreading (i.e., the evolving contact
surface area) per se since this is a major factor in delivery. A
succession of fluid mechanical models was developed
[17–23]. A semi-empirical algorithm for drawing inferences
about drug delivery from the original gel spreading model was
developed and applied [24–26]. Recently, we introduced the
first deterministic, computational model of mass transport by a
drug from a vaginal gel into the vaginal mucosal tissue [14].
Here, the geometry of the processes was simplified: There was
complete gel coating of the surfaces of the vaginal canal at a
constant thickness. The model was applied quantitatively to
the tenofovir gel that is currently in extended clinical testing,
and good agreement was found between predictions of it and
human PK data (see BDiscussion^). However, that model was
limited in that it computed only tenofovir concentrations, not
those of its bioactive form, tenofovir diphosphate. Further, this
model cannot capture the effects of time-dependent gel
spreading along the vaginal canal and possible leakage from
the vaginal opening, the introitus. Consequently, the model
cannot distinguish consequences of spreading by gels with
different properties and volumes in canals with different di-
mensions and of different locations of gel insertion along the
canal. Indeed, vaginal gel spreading models, to date, have
neglected these latter factors and have used a bilaterally sym-
metrical spreading model along a canal of infinite extent.
The present analysis is the logical next step in development
and application of models of vaginal gel deployment and drug
delivery into and throughout the vaginal environment. First,
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we introduce improvements in the theory of drug mass trans-
port within and between compartments, accounting for gel
spreading and leakage. Then, we apply the new theory to three
prototype microbicide gels with contrasting rheological prop-
erties and consider variations in gel volume and drug loading.
In doing so, we address the consequences of salient factors in
gel use, including varying vaginal size and site of gel insertion
within the canal. We contrast vaginal spreading and gel leak-
age vs. time for the three test gels. These results are input to
computations of the time and space histories of tenofovir and
tenofovir diphosphate concentration distributions. Such pre-
dictions can and are compared to direct experimental measure-
ments in studies of drug pharmacokinetics. We also begin to
interpret predicted tenofovir diphosphate concentration distri-
butions with respect to target concentrations believed to be
prophylactic against HIV. On the basis of an EC50 value for
TFV-DP in cells against HIV, we compute a measure of TFV-
DP concentration distribution in vaginal stroma that may be
related to potential gel prophylactic efficacy (PD). Termed
Bpercent protected,^ this is a summary metric of gel product
tenofovir delivery performance. It is a function of time and
provides insights about the length the interval following gel
insertion after which maximum protection is created, the mag-
nitude of that protection, and its duration. These results can
thus inform instructions to gel users about the safe interval of
protection between gel insertion and sex. They can comple-
ment information derived from experimental PK studies
which, by nature, are limited in the numbers of samples and
sample times that can be implemented and in which data are
beset by high variability [27, 28]. Together with the computa-
tions of gel leakage, they can guide decisions about optimal
combinations of volume and drug loading for gels with par-
ticular rheological properties. Overall, our goal is to introduce
a computational tool that can be used in the design and per-
formance evaluation of current microbicide products and in
the development of improved ones.
Materials and methods
Drug delivery in the vaginal mucosa by a gel placed into the
canal derives from two interacting mass transport processes:
gel flow after insertion due primarily to squeezing by the walls
of the canal [22] and drug diffusion out from gel and into
tissue. Gel flow is essentially independent of drug transport
and, thus, can be analyzed first and then input to solution of
the complete convection–diffusion drug transport problem.
Here, we introduce improvements to prior models of vaginal
gel spreading. Characterization of some geometric details of the
human vaginal canal is simplified to facilitate some aspects of
model implementation and interpretation. The simplifications
are sufficient to enable a model to capture the essential physics
of its transport process, while enabling initial comparisons with
experimental results (see BDiscussion^). The human vaginal
canal has a cross-section that is approximately rectangular, with
height small compared to width (typically about 2.5 cm), which
in turn is small vs. axial length (ranging from about 10–15 cm
[29, 30]). The internal cervical os inserts into the vaginal fornix
at an oblique angle. The cervical canal is filled with mucus that
constrains gel flow from the fornix into it. Both the outer open-
ing (the introitus) and opening in the innermost wall of the
vaginal canal connect to larger spaces: the introitus to the out-
side of the body and the os in the fornix to the upper female
reproductive tract and peritoneal cavity. We assume that ambi-
ent pressure at the introitus and external cervical os is relatively
constant and small compared to the time-dependent pressure
within the canal, which is increased due to squeezing by the
vaginal walls. Fluid mechanical lubrication theory can be ap-
plied for vaginal gel flow [17, 18], and the geometry can be
reduced to a two-dimensional rectangular channel [18, 22]. We
neglect variations across the width of the cross-section (the
third dimension) and assume that pressure at the introitus is
atmospheric. Gel is typically inserted as a bolus by a piston-
type applicator. The bolus distends the canal walls, and consis-
tent with the squeezing channel geometry, we assume that the
shape of the bolus is rectangular and that it fills the height of the
canal (Fig. 1) [22]. Initial gel placement influences its flow over
time because (1) gel may spread to an extent that its outermost
edge leaks from the introitus and/or (2) the innermost edge of
gel may flow up to the inner wall of the fornix and thence cease
to move. In our analysis of gel spreading, we use a Cartesian
coordinate system with origin (y=0) in the midplane of the gel
and canal. Anatomically, the longitudinal position of the origin
(x=0) depends upon site of gel insertion (Fig. 2). Flow and drug
Fig. 1 Geometrical features of the gel flow and drug transport problem,
showing the epithelial and stromal layers of the mucus with a gel bolus
inserted in between. a Physically realistic model; the arrows indicate
variable squeezing force that is proportional to vaginal wall
displacement. b Our rectilinear model geometry that approximates this;
the arrows indicate total squeezing force from the vaginal wall. The
problem is symmetrical about y=0 (dotted line). For the human, a
typical length of the vaginal canal is 13 cm and width is 3.35 cm.
Typical thicknesses of epithelial and stromal tissue of the mucosa are
200 μm and 2.8 mm respectively (details are discussed in text)
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transport are symmetrical about y=0. The microbicides field
has experimented with gel volumes ranging from 2 to 5 mL,
with a 5-mL gel showing significant leakage. In our analyses,
we picked gel volumes of 2 and 4 mL as representative values
that span the likely range of volumes of future products.
Analysis of gel flow along the lumen of the vaginal canal
Given that the site of initial gel placement can vary along the
length of the canal, we define four configurations of flow that
span the range of geometric possibilities. These differ in rela-
tion to whether or not the distal gel edge (moving outwards
towards the introitus) and proximal edge (moving inwards
towards the inner boundary of the fornix) reach those bound-
aries during the time course of flow (Fig. 2). If the distal edge
reaches the introitus, the gel will leak out of the flow domain
thereafter. If the proximal edge reaches the inner boundary of
the fornix, subsequent gel flow will be unidirectional towards
the introitus. Depending upon the parameters of the problem
(gel rheology and volume and vaginal dimensions), the over-
all flow during the time course of interest may be a sequence
of two or more of these cases.
Spreading of gel along the canal is a biomechanical flow
problem for a non-Newtonian fluid in a channel with elastic
walls that exhibit a squeezing force against it [17–20].
Mathematical details of our solution of this problem are in
the Supplementary Material section. In this analysis, we char-
acterize the rheological behavior of the gel using the Carreau-
like constitutive model, which relates local shear stress in the
gel to local shear strain rate [18]. In doing so, we include the
possible presence of a yield stress in the gel. This constitutive
equation is preferable to the Power Law constitutive model
used in the initial modeling of vaginal gel flow [17, 31] be-
cause it more accurately accounts for the low shear strain rate
behavior of the gel, which is characteristic of vaginal coating
flow and which plays a major role in governing flow rate.
We applied this modeling schema to three gels that were
created with rheological properties that bracket a range of
those postulated to be candidates for vaginal microbicide gels,
producing a range of spreading rates along the canal. This
provided contrasts in how tenofovir delivery was influenced
by gel rheology as well as other factors. Additional physico-
chemical gel properties (e.g., osmolality and pH) were not
tuned to final values suitable for in vivo gel evaluations. Gel
compositions are given in Table 1.
Gel rheological properties were measured at body temper-
ature (37 °C) using a constant stress protocol on a TA
Instruments model AR 1500ex rheometer (4° cone and 20-
cm plate configuration [19, 20]). Shear rates ranged 10−4 to
250 s−1. Residual stresses of gels weremeasured, as surrogates
for yield stress by stress relaxation experiments in a
Brookfield 5HB DV-III Ultra rheometer with a CPE-40 cone
[19, 32]. The gel was initially stressed at 10 s−1 for 5 min and
then relaxed for 14 min, during which time stress was mea-
sured to determine a limiting value. Results are given in
Table 2.
Drug transport into epithelial and stromal layers
of the vaginal mucosa
Drug transport from gel into the vaginal mucosa is character-
ized in our model by a two-dimensional unsteady convection–
diffusion mass transport process. The vaginal mucosa consists
of two histologically different layers, the epithelium and stro-
ma (Fig. 1). In humans, the upper epithelial layer has a strat-
ified squamous cell structure, but no vasculature. The stromal
layer is made up of connective tissue and some cells (a subset
of which are infectible by HIV) and contains blood and lym-
phatic vessels which drug enters. Our model contains four
different compartments, in each of which conservation of
mass is applied: gel, epithelium, stroma, and the blood (which
is taken as a spatially homogeneous compartment [28, 14,
27]). Drug transport is due to diffusion (in gel, epithelium,
and stroma) and convection (in gel and vaginal fluid adjacent
to it). Vaginal fluid is not taken as a separate compartment, but
gel dilution by it is included in modeling mass transport in/out
from the gel. The diffusion coefficient of drug in the gel is
several orders of magnitude higher than the diffusion coeffi-
cient(s) in the tissue compartments [14]. We found, conse-
quently, in our prior one-dimensional model that the time-
dependent drug concentration in the gel was nearly uniform
with depth, and we make that assumption here. Drug transport
Fig. 2 Four different cases of the extent of gel flow over the time interval
of interest for different locations of initial gel bolus placement. The
introitus of the vagina is the opening on the left side of the figure; the
cervical canal inserts at an angle at the right. Gel profile is shown in blue.
a Gel is initially placed in the canal; flow is bilaterally symmetric. b Gel
has begun to leak; the flow is symmetric about midpoint of the gel in the
vagina. c Gel has reached the end of the fornix; flow is towards the
introitus only. d A combination of b and c, where the gel has coated the
entire length of the canal
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in both the epithelium and stroma remains a two-dimensional
diffusion-driven process. Tenofovir diphosphate production is
included in the epithelial and stromal compartments, which
contain cells that tenofovir enters and become phosphorylated.
The stroma contains HIV-infectible host cells that are believed
to be a primary source of HIV transmission. Thus, the TFV-
DP concentration in the stromal host cells is a primary output
of the model. The conservation of mass equations for
tenofovir and tenofovir diphosphate are as follows:
Here, concentrations are defined as per unit volume of the
matrix (viz. the four compartments). Equation (9a) gives
change in concentration CG in the gel compartment, where
DE is the diffusion coefficient in the epithelium and CE is
concentration in the epithelium, w is the width of the canal,
L is the distance from the center to the edge of the gel, and VG
is the gel volume. The integral gives total mass of drug leaving
the gel to the epithelium. Drug concentration in gel is also
reduced due to imbibing of ambient vaginal fluid, and this is
modeled as a first-order process with rate constant kD [14].
Drug transport in epithelium (Eq. (9b)) is a two-dimensional
unsteady diffusion process, CE is concentration, and DE is the
diffusion coefficient. The last two terms of the equation are the
creation and elimination rate for tenofovir diphosphate, where
kon is the formation rate of TFV-DP, koff is the elimination of
and r is the fraction of TFV converted to TFV-DP within the
cells. Drug transport in stroma (Eq. (9c)) is also a two-
dimensional unsteady diffusion process with a first-order loss
term for uptake into the vasculature with rate constant kB [14];
Cs is concentration, and DS is the diffusion coefficient. The
TFV-DP production mechanism is taken to be similar to the
one in the epithelium except with a different host cell volume
formly throughout the stromal layer. In the blood compart-
ment (Eq. (9d)), the mass balance of concentration CB is
governed by the input from the stroma divided by VB (the
volume of the blood compartment) and loss due to metabolism
by the body (with first order rate constant kL, typically given
as a volumetric value [33]). The time rate of change for TFV-
DP (Eq. (9e)) has two components on the right hand side of
the equation. The first is the rate of formation kon multiplied by
the difference between the current level of TFV-DP and the
saturation level based on the local tenofovir concentration
CTFV in the epithelium or stroma, the proportion of host cells
This term is inside Macaulay brackets {} (defined such that
the expression inside the brackets is 0 when it is computed to
be negative; the TFV-DP formation rate must be strictly pos-
itive or 0). The second component is the rate of elimination or
Table 1 Compositions and











DG-01 3.00 2.50 0.20 0.05 93.25 360±16 5.78
DG-02 4.00 2.00 0.20 0.05 92.75 355±14 5.82
DG-03 1.50 2.00 0.20 0.05 95.25 331±41 5.58
HEC hydroxyethylcellulose
Table 2 Rheological parameters
of the three test gels based on the
Carreau-like constitutive model
Gel Yield stress τ0
(dyne/cm2)
Zero shear viscosity m0
(poise)






20 3820 1300 0.261
DG-
02
380 2070 1960 0.219
DG-
03
0 175 153 0.344





















































TFV-DP, φE is the volume fraction of cells in the epithelium,
fraction φS. The blood vessels are distributed relatively uni-
φ, and the fraction r of TFV that can be converted to TFV-DP.
the conversion from TFV-DP to TFV governed by the rate
constant koff.
Boundary and initial conditions for the system of
Eqs. (9a)–(9e) are given in Eq. (10).
CG ¼ ΦGCE @ y ¼ 0; 0≤x≥Lð Þ ð10aÞ
∂CE
∂y
¼ 0 @ y ¼ 0; x > Lð Þ ð10bÞ
CE ¼ ΦECS ; DE∂CE∂y ¼ DS
∂CS
∂y
@ y ¼ hEð Þ ð10cÞ
∂CS
∂y
¼ 0 @ y ¼ hE þ hsð Þ ð10dÞ
∂CE
∂x
¼ 0 @ x ¼ 0 and x ¼ dð Þ ð10eÞ
∂CS
∂x
¼ 0 @ x ¼ 0 and x ¼ dð Þ ð10f Þ
CG t0ð Þ ¼ C0 ð10gÞ
CE t0ð Þ ¼ 0 ð10hÞ
CS t0ð Þ ¼ 0 ð10iÞ
CB t0ð Þ ¼ 0 ð10jÞ
CDP t0ð Þ ¼ 0 ð10kÞ
The coordinate system here is different from that in gel
spreading computations; the origin is at the top left corner of
the tissue layer. The gel is inserted at time to, which is taken as
0 in the computations here. Partition coefficients between gel
and epithelium and epithelial and stromal compartments are
ΦG and ΦE, respectively. Thicknesses of the epithelium and
stroma are denoted hE and hS, and d is the distance along the
canal from introitus to fornix.
Numerical solution of the equations of the model
We solve the system described in Eqs. (9) and (10) using
Matlab [34]. Epithelial and stromal compartments are rep-
resented as rectangular regions with xy grids. After estab-
lishing the coordinates, we convert Eqs. (9a)–(9c) from a
system of partial differential equations to a system of or-
dinary differential equations using centered difference for-
mulas for first and second derivatives. We input results
from the model for gel spreading and leakage described
above. We determine the half-length L of the gel (Eq. 9a)
in contact with the tissue surface from the gel spreading
model. This length is discretized to fit into the space of
the two-dimensional drug transport problem. The solution
at each point in the space is now described by a system
of ordinary differential equations that are solved in MATL
AB using the Runge–Kutta 4,5 method. Output of the
MATLAB computation gives concentrations of drug in
gel, epithelium, and stroma in time and space. We solve
Eq. (9d) separately from the rest of the system to find the
drug concentration in the blood. The equation is a simple
first-order ordinary differential equation with an input term
that is dependent on the calculated stromal drug concen-
tration. The solution to the TFV-DP term in Eq. (9e) is
coupled with the solution to the tenofovir Eq. (9a–c) and
is solved simultaneously in the overall system of differen-
tial equations.
Parameters in the model
There are a number of parameters in this model (Table 3).
These are largely the same parameters used in our initial anal-
ysis of the problem (with uniform coating along the entire
length of the vaginal canal [14]). We take the epithelial and
stromal layer thicknesses as 200 μm and 2.8 mm, respectively
[35]. The model contains values of the length d and widthw of
the vaginal canal. These vary amongst women [30]. In apply-
ing the model, based on the range of human vaginal morpho-
metric data, we consider three representative cases: an
Baverage size,^ a Bsmall size,^ and a Blarge size.^ We use
the small and large sizes to contrast rates and extent of coating
by the three test gels. We use the average size in performing
follow-up mass transport computations of drug concentration
distributions. These latter computations require values for the
three rate constants: for gel dilution, drug loss to the vascula-
ture in the stroma, and drug loss from the bloodstream, kD, kB,
and kL, respectively. We obtained these using comparisons of
model predictions for the clinical tenofovir gel with human
pharmacokinetic (PK) data for drug concentrations in vaginal
tissue biopsies and blood samples [27]. We apply those same
values here. Using Stokes Einstein theory, we deduced values
of the diffusion coefficient to be 6×10−6 cm2/s in the gels. All
are highly hydrated, and the relatively small differences in
diffusion coefficient that might occur across the three gels
have a minor impact on our drug transport computations (sim-
ulation data not shown). We used the values of diffusion co-
efficients for tenofovir in epithelium and stroma as 7×10−8
and 4×10−7 cm2/s, respectively, and the value of 0.75 for the
partition coefficient at the interface between gel and epitheli-
um. These were derived from initial experimental mea-
surements of tenofovir transport in specimens of fresh
porcine vaginal tissue using confocal Raman spectrosco-
py [36]. The kinetic parameters for TFV-DP, kon, and
koff were estimated based on PK studies of TFV-DP
formation [37]. We note that these studies measured
varying TFV-DP clearance rates in different cell types;
however, all are quite slow (TFV-DP is retained over
the order of days). Such differences in the values of koff
for TFV-DP have negligible effect on results here, which are
limited to 24 h after gel application. The value of VB, volume
of distribution in the blood compartment, was taken as 75 L
[33].
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Results
Gel flow along the lumen of the vaginal canal
Flow of a gel bolus over the epithelial surfaces of the vaginal
canal can be characterized by the instantaneous length of the
bolus along the surfaces as a function of time; this is propor-
tional to the coated surface area in our rectilinear model. Two
salient measures of the flow are the time-dependent percent of
the total epithelial surface coated by a gel and the gel volume
that has leaked out from the introitus. Figures 3 and 4 plot
these twomeasures for the three test gels DG1, DG2, and DG3
for volumes 2 and 4 mL. Those volumes span the range of
potential vaginal microbicide gel volumes being considered.
The two different vaginal sizes are termed Bsmall^ (length d=
12 cm, width w=3 cm, surface area A=72 cm2) and Blarge^
(length d=15 cm, width w=3.5 cm, surface area A=105 cm2).
Two different sites of initial placement of the gel bolus are
considered: one at the inner end of the canal at the fornix
(l0=12 cm and l0=15 cm) and one midway along the canal
(l0=6 cm and l0=7.5 cm) for small and large sized canals,
respectively. Results are plotted up to 24 h after gel insertion
in order to display the approach to steady state of gel spread-
ing. As seen in the shapes of the plots, coated area achieves a
nearly steady-state value or gel begins to leak by about 12 h.
Further, we caution that these computations model gel spread-
ing in the absence of significant body motions by the user and
thus likely apply to intervals no greater than 8–12 h (this
limitation in gel flow analysis has minimal effect, however,
on drug transport within the mucosal layers at times up to
24 h; see BDiscussion).^
Gel DG3 is the least viscous and exhibits no yield stress;
thus, this gel spreads the fastest. DG2 is the opposite, having a
high yield stress and exhibiting a higher viscosity over the
range of shear rates expected in vivo. This gel was created
with the intention that it flows very slowly and thus remains
near the site of insertion. Thus, although it does not tend to
spread, this gel is alsomuch less likely to leak. The rheological
properties of gel DG1 are intermediate between those of DG2
and DG3. Although this gel does not have a significant yield
stress, it does not spread as rapidly as DG3. The spreading
kinetics of all gels are similar in that there are a short time
scale during which spreading is relatively rapid and a longer
time scale over which the spreading rate is much slower.
Depending upon the site of placement, gel volume, and rheo-
logical properties, the gel may begin to leak during flow over
either of these two time scales. If a yield stress is present, the
spreading rate eventually diminishes to zero, at which the
squeezing force and the gel resistance to deformation embod-
ied by the yield stress are in equilibrium.
There are differential interactions amongst gel properties,
volume, vaginal size, and site of gel insertion. The spreading
and leakage plots for DG1 in (Figs. 3a and 4a) show that at
4 mL, this gel spreads relatively rapidly, completely coating
the lumen in 2–8 h after insertion, depending upon site of
insertion and vaginal size. However, it also exhibits leakage
of about 0.5–1 mL over 24 h depending again upon site of
insertion and vaginal size. Applying a 2 volume of gel DG1
results in lower coated area which is more dependent on initial
position. The 2-mL volume produces no leakage over 24 h.
Given its relatively high yield stress, gel DG2 does not coat
completely over 24 h and thus does not leak (Figs. 3b and 4b).
Table 3 Parameters used in the
drug mass transport model Parameter Symbol Value
Gel diffusion coefficient (cm2/s) DG 6×10
−6
Diffusion coefficient for TFV in epithelium (cm2/s) DE 7×10
−8
Diffusion coefficient for TFV in stroma (cm2/s) DS 4×10
−7
Gel/epithelium partition coefficient ΦGE 0.75
Epithelial thickness (cm) hE 0.02
Stromal thickness (cm) hS 0.28
Rate constant due to dilution in gel (h−1) kD 1.22
Rate constant to blood vessels in stroma (h−1) kB 0.119
Rate constant for loss in blood (h−1) kL 1.41
Rate of formation of TFV-DP (h−1) kon 0.693
Rate of elimination of TFV-DP (h−1) koff 0.00413
Volume fraction of host cells in epithelium, stroma 0.95, 0.1
Proportion of TFV-DP converted from TFV r 0.1
Initial concentration in gel (ng/ml) C0 10
7
Volume of distribution for blood (L) VB 75
Length of vaginal canal for small, average and large vagina (cm) d 12, 13, 15
Width of vaginal canal for small, average and large vaginal (cm) w 3, 3.35, 3.5
Surface area for small, average, large vagina (cm2) A 72, 87.1, 105
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φe, φs
The coated area is clearly dependent on volume and site of
placement. By 24 h, a 2-mL volume coats between about 35
and 60 % of the epithelial surface and 4 mL coats between 45
and 75 %, depending upon the site of placement and vaginal
size.
Figures 3c and 4c show clearly that gel DG3 flows very
rapidly. Both volumes of this gel coat the entire epithelial
surface within 72 min, and it also leaks to a very high extent.
By 24 h, only about 0.8 mL of the initial volumes of this gel is
retained within the vaginal canal, and the initial position has
little effect, especially at longer times.
Drug transport into the epithelial and stromal layers
of the tissue
Multidimensional, time-dependent tenofovir and tenofovir
diphosphate concentration distributions in epithelium
and stroma
Drug transport from a spreading gel into the mucosal tissue
can be characterized by a spatio-temporal map of
concentration, here in two dimensions (depth into tissue and
distance along the vaginal canal) and time. This is illustrated
by an animation for 3 mL of gel DG1 (inserted at the inner end
of a vaginal canal of average dimensions; see Supplemental
Material). Still, images at 1, 2, 4, and 24 h are shown as heat
plots in Fig. 5. Here, thicknesses of the epithelial and stromal
layers are 0.02 and 0.28 cm, respectively. The x- and y-axes
are in directions longitudinal and transverse to the tissue sur-
face; x ranges from 0 cm at the introitus to 13 cm at the
innermost end of the canal, and tissue depth ranges from
0 cm at the tissue surface to 0.3 cm at the lower margin of
the stroma.
Concentration distribution of TFV longitudinally in tissue
closely maps with the longitudinal extent of gel spreading.
The leading edge of gel (Fig. 5) is effectively the leading edge
of the TFV concentration profiles. Peak concentrations in tis-
sue diminish over time, as gel spreads further along the canal
and as drug diffuses down into the tissue and is cleared within
the stromal layer. At times up to 4 h, the maximum concen-
tration in the tissue is about 107 fmol/mg, and concentration
remains at above 105 fmol/mg throughout most of the stroma.
Fig. 3 Fractional area coated and leakage volume over time for gels
DG1(a), DG2(b), and DG3(c) inserted at position L0 in the canal with
volumes 2 and 4 mL. These results are for a morphometrically large
vaginal canal, length d=15 cm and width w=3.5 cm. L0=15 cm
corresponds to gel insertion into the fornix, and L0=7.5 corresponds to
gel insertion to the midpoint along the vaginal canal. Gels DG1 (2 mL)
and DG2 (both volumes) do not leak. Gel DG3 spreads very rapidly, and
both volumes achieve complete coating within 72 min
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At 24 h, the tissue has a concentration between 104 and
105 fmol/mg. The longitudinal concentration distribution of
TFV-DP also maps with gel spreading. Concentration (per
unit tissue volume) is higher in the epithelium than stroma
because of the higher concentration of cells. Overall, TFV-
DP concentration distribution follows that of TFV for relative-
ly short times. However, for longer times (viz>8 h), TFV-DP
concentration approaches a steady-state value because of its
very low clearance rate.
Volume-averaged concentrations in compartments vs. time
Volume averages vs. time of drug concentration distributions
in each compartment (gel, epithelium, stroma, and blood [in
which concentration is homogeneous]) yield plots analogous
to measurements of drug concentrations in experimental phar-
macokinetic studies [27]. Figures 6 and 7 give examples of
such plots for gel volumes 3 mL (DG1), 4 mL (DG2), and
2 mL (DG3).We chose volumes for each gel (within the range
2–4 mL) that give coating at 24 h which is closest to the
surface area of the vaginal canal. While not strict optima, the
three selected values of gel volume do provide an instructive
example of conditions that illustrate pharmacologically rele-
vant outputs of the model. In these computations, we used
dimensions representing an averaged sized vagina: length=
13 cm and width=3.35 cm; epithelial thickness was again
0.02 cm. Here, we conserved total mass of loaded drug in
gel across volumes (an alternative example would have been
to conserve initial concentration; see additional computations
below). Thus, initial drug concentration is inversely propor-
tional to gel volume. We chose a value Mo=40 mg, which is
the tenofovir mass in the 4-mL volume of the clinical micro-
bicide gel used in trials [8, 38].
From Fig. 6, we see that insertion of all gels to the fornix
gives lower TFV concentrations in the epithelium and stroma
than insertion to the middle of the canal. Stromal AUC values
are about 15, 30, and 1 % lower for gels DG1, DG2, and DG3
(computations not shown). From Fig. 7, we see that average
stromal concentrations of TFV-DP follow the same pattern for
all three gels. They rise to a quasi-steady-state value in about
6 h for all gels and then remain nearly constant beyond the
interval of computation (because of the very low loss rate
Fig. 4 Fractional area coated and leakage volume over time for gels
DG1(a), DG2(b), and DG3(c) inserted at position L0 in the canal with
volumes 2 and 4 mL. These results are for a morphometrically small
vaginal canal, length d=12 cm and width w=3 cm. L0=12 cm
corresponds to gel insertion into the fornix, and L0=6 corresponds to
gel insertion to the midpoint along the vaginal canal. Gels DG1 (2 mL)
and DG2 (both volumes) do not leak. Gel DG3 spreads very rapidly, and
both volumes achieve complete coating within 15 min
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constant for TFV-DP). Peak values of TFV-DP concentrations
are higher for gel insertion to the middle of the canal by about
15, 40, and 0.5 % for gels DG1, DG2, and DG3, respectively.
Thus, results for gel DG3 (the lowest viscosity, relatively
Brunny^ gel) are relatively insensitive to site of insertion be-
cause it coats the entire length of the canal so rapidly. Overall,
results in Fig. 7 indicate that the rank ordering of effective
drug delivery performance (i.e., TFV-DP concentrations in
stroma) for the gels is DG3 (2 mL)>DG1 (3 mL)>DG2
(4 mL).
Volume of stromal layer containing HIV prophylactic
concentrations of tenofovir diphosphate
The pharmacodynamic potency of tenofovir is manifest
through concentrations of tenofovir diphosphate in HIV-
infectible cells. Many diverse studies have investigated this;
the great majority of which focused upon the relationship
between tenofovir concentrations in infectible tissue and the
infectibility of that tissue. A one log range of EC50 values for
tenofovir has emerged [33]. Fewer studies have focused upon
the relationship between concentrations of tenofovir diphos-
phate and HIV infectibility. The problem is compounded by
the fact that different HIV-infectible cell types produce differ-
ent intracellular TFV-DP concentrations, that such production
in cells in the female reproductive tract is regulated by estra-
diol and/or progesterone, and that different cell types appear to
have different inherent TFV-DP dose response behavior. In
the analysis here, we focus on a 2 log range of the putative
EC50 value for TFV-DP in stromal host cells.We compute the
fraction of the total volume of the stromal layer (and, thus, the
host cells therein) that instantaneously achieves a TFV-DP
concentration≥ this EC50 reference value. This fraction,
termed percent protected, may thus relate to prophylactic
Fig. 5 Concentration distributions in tissue at 1, 2, 4, and 24 h for a 4-mL
DG1 gel inserted at the inner end of a vaginal canal with length and width,
13 and 3.35 cm, respectively (morphometrically average dimensions, see
text). The epithelium is 0.02-cm thick and the stroma is 0.28-cm thick.
The gel spreads from right to left. The colors represent local drug con-
centration on the log scale plotted over the range <10−2 to 107 fmol/mg
(see attached video for full 24 h animation)
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effectiveness against HIV. It is an objective, mechanistically
derived measure that can be related to the characteristics of the
gel, drug, vaginal environment, etc. (viz. as presented above
for measures of gel spreading, tenofovir transport, and
tenofovir diphosphate production). We based the range of
EC50 values for tenofovir diphosphate by referencing the
lower bound value of 0.5 μM for tenofovir [33] TFV-DP
concentrations in human vaginal biopsies after dosing with
the 1 % TFV gel are approximately two logs lower than the
measured TFV concentrations. Hence, we chose 0.005 μM (5
fmol/mg) as the lower bound of the EC50 for TFV-DP here.
We conservatively used an upper bound for this EC50 value
for TFV-DP that is 2 logs higher. Figure 8 illustrates applica-
tion of this computation to gels DG1, DG2, and DG3, varying
gel volume and tenofovir loading. This exercise provides in-
sight into practical decisions that developers must make, once
a gel composition has been decided, about what volume to
apply and whether variations in loaded drug concentration
(compatible with safety, stability, and solubility requirements)
are needed. For each gel, we used, as a reference condition, a
volume giving rise to a coated area in 1 h as close as possible
to that of the vaginal canal; for this reference condition, loaded
TFV concentration was 1 % (as in the clinical TFV gel).
Because gel DG2 coats so slowly, we did increase its reference
volume from 4 to 5 mL (vs. results shown in Figs. 6 and 7).
Fig. 6 Volume-averaged TFV concentrations in gel, epithelium, stroma,
and blood compartments over time for the three gels inserted to the
middle and innermost end (the fornix) of a vaginal canal with average
morphometric dimensions (see text). Total mass of loaded drug is
conserved over all gel volumes, Mo=40 mg
Fig. 7 Volume-averaged concentrations of TFV-DP in stroma over time
for the three gels inserted to themiddle and innermost end (the fornix) of a
vaginal canal with averagemorphometric dimensions. Total mass of load-
ed drug is conserved over all gel volumes, Mo=40 mg
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We then perturbed either the reference gel volume or TFV
concentration: Volume was reduced while maintaining TFV
concentration (termed BTFV concentration conserved^) or
volume was reduced, but concentration was altered to achieve
the same mass of drug loaded into gel as for the reference
condition (termed BTFV mass conserved^). Average vaginal
dimensions of 13 by 3.35 cm were used to represent an aver-
age size, and gel was inserted into the fornix.
From Fig. 8, we see a steep rise in percent protected during
the first 2–4 h after gel insertion; after which, the curve bends
over and approaches a maximum value over a range of times
from almost instantaneous (gel DG2) to several hours (gel
DG1). Thus, protection evolves initially at a fast rate during
an interval in which at least 90 % of its maximum value of
percent protected is reached. This peak value is sustained at
near steady state because of the very slow clearance of TFV-
DP from cells. The time scale of analysis here is ≤24 h post-
gel application. Although there appears to be some variation
in the duration of clearance rate of TFV-DP amongst cell
types, all reported rates are on time scales much greater than
24 h [39, 40]. Consequently, differences amongst them have
minimal impact on the curves in Fig. 8. We can characterize
the behavior of percent protected in terms of the time to reach
the bend-over point in the curve (an effective tbend) and the
peak value of percent protected (an effective PPmax at the
longer, quasi-steady-state times). For all gels, the highest gel
volume achieves the highest percent protected the most rapid-
ly. Reducing that volume (e.g., for cosmetic reasons) while
Fig. 8 Plots of percent protected vs. time for the three test gels, DG1,
DG2, and DG3. For each gel (different rows), the reference EC50 for
tenofovir diphosphate is varied by 2 logs (different columns) as 5, 50,
and 500 fmol/mg. Further, three combinations of gel volume and initial
tenofovir concentration (Co) are considered: (1) a reference combination
(green line) intended to produce the highest percent protected per gel, (2)
conservation of Co from condition 1 and reduction of gel volume (so that
Mo, the mass of loaded TFV, is conserved), and (3) conservation of Mo
from condition 1 (so that initial concentration Co is increased)
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conserving either loaded TFV concentration or mass of TFV
loaded produces indistinguishable results. That is, gel volume,
not loaded TFV concentration, is the dominant factor.
However, quantitative differences across volumes and drug
loadings are negligible for gel DG3. This gel, which has a
low viscosity, achieves peak values (100 %) the fastest across
the three gels, even though the mass of drug in it is the lowest
across the conditions considered. This is because the gel
spreads so rapidly, creating a thin coating layer across which
TFV diffuses more rapidly than in the thicker layers for the
other two gels. The higher volume (4 mL) for gel DG1, loaded
at 1 % TFV, achieves ~100% protection, but more slowly than
for DG3. Reducing its volume reduces the peak value to about
90 %. This results from the competition between increased
TFV delivery due to increased coating and the loss of TFV
due to gel leakage plus clearance of TFV in the stromal layer.
Gel DG2, the very high viscosity gel, never achieves more
than 60 % protected because it only coats a fraction of the
length of the vaginal canal. For all gels, the effect of increasing
the threshold EC50 value for protection is to increase the time
interval over which the steep rise in percent protected occurs
(tbend increases); however, this 2 log variation of the EC50 has
little effect on the maximum value achieved of percent
protected (PPmax).
Discussion
Topically acting microbicides are an important modality that
could complement vaccines in the fight to stem the AIDS
pandemic. Gels have been a primary delivery platform being
developed for vaginal microbicide application. However, no
gel, to date, has successfully completed phase 3 trials. Failures
of adequate participant adherence in the VOICE and FACTS
trials raise the question of whether or not the gel dosage form
can achieve adequate willingness to use in target populations.
Thus, it is logical to consider what characteristics of gels, their
design, and their application processes might be improved to
foster better willingness to use without compromising prophy-
lactic activity. The deterministic approach embodied in the
modeling here—which computes and links gel spreading/
leakage to drug delivery—could contribute to evaluation of
the prospects for improved design of gels and their applied
volumes. Improved gels could, for example, be less messy and
more discreet, while still achieving effective PK and PD. By
helping in prediction of the interval of maximum protection
after gel insertion, the model here could also inform instruc-
tions to users about proper gel use. Although the computations
were for tenofovir, the deterministic approach here is robust to
multiple drugs. The computational model here is also for con-
ditions in which gel is applied prior to sexual activity.
Interpretation of the percent protected measure here can none-
theless address salient questions about gel use to prevent
vaginal HIV transmission, viz: (1) how long the users must
wait following gel insertion and prior to sex to achieve pro-
tection (captured in the tbend) and (2) how good that protection
is (captured in the PPmax).
We note that computations here extend to 24 h post gel
insertion. Towards the end of this interval, details of gel
spreading per se likely become more complex than as simu-
lated in our model, as a woman’s activity contributes addition-
al forces against the gel, and further dilution with ambient
fluids occurs. However, we also note that drug remaining in
a gel at those later times is nearly depleted (Fig. 6) and lumen-
al drug in the vagina has minimal impact on drug transport
through the mucosal layers at such times. Consequently, we
believe that our computations of drug distribution in epitheli-
um and stroma (viz. Figs. 6 and 7) are not compromised.
Gel spreading
Results in Figs. 3 and 4 show broad ranges in rate and extent
of gel spreading and leakage across the three gels, three vol-
umes, and two sites of initial gel placement. There are current-
ly no standards for rheological properties or volumes of vag-
inal (or rectal) microbicide gels, and it was thus logical to
create these test gels to embody a broad range of spreading
behavior. The rate of spreading has an inverse relationship
with gel viscosity and yield stress and a direct relationship
with gel volume, over variations in vaginal canal size and site
of gel placement (Figs. 3 and 4). Of course, vaginal canals of
greater length and width will accommodate larger gel volumes
without leakage.
Drug mass transport
Mass transport of tenofovir from a gel is a time- and space-
dependent process, within as well as between compartments
(Fig. 5). Because drug mass transport longitudinally along the
canal maps with the position of the leading edge of the gel,
relatively good spreading (gels DG1 and DG3) ensures drug
distribution along the length of the vaginal mucosa while lim-
ited gel spreading (gel DG2) delays such distribution, the
presence of vaginal fluid notwithstanding.
Because total mass of TFVand TFV-DP in epithelium and
stroma scales with rate of gel spreading, the curves for average
TFV and TFV-DP concentrations have the same qualitative
shape across gels (Figs. 6 and 7). The curves for TFV look
very different from those for TFV-DP because the long half-
life of TFV-DP in cells causes its average concentration in
stroma to plateau at about 4–6 h. In contrast, average TFV
concentrations in epithelium, stroma, and blood rise to Cmax
values and then decline, as supply from gel diminishes and
drug is cleared in stroma and blood.
TFV and TFV-DP concentrations in epithelium and espe-
cially stroma exhibit sharp spatial concentration gradients
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with depth at early times (Fig. 5). Then, TFV concentration in
the epithelium flattens out as drug in the gel is depleted during
the first 2–3 h (cf. Figs. 5 and 6; see also Fig. 2 from reference
22). TFV in the stromal layer accumulates in the upper few
hundred micrometers of thickness, and concentration distribu-
tion flattens out as it drops by about 2 logs during 24 h (Fig. 5;
see also Fig. 2 from reference 22). As a result, TFV-DP con-
centration in the stroma is much higher in these upper few
hundred micrometers of that layer than below; consequently,
the spatial average concentration of TFV-DP throughout the
depth of the stroma is relatively high (compared to the target
EC50 values) regardless of the rate of gel spreading. This is
discussed further in the next section.
We compared predictions using this model with human PK
data for the 1 % tenofovir gel inserted at 4 mL for a vaginal of
average dimensions [27]. Using our rheological data for that
gel, we computed TFV concentrations vs. time in gel, epithe-
lium, stroma, and blood compartments for up to 24 h post-gel
insertion. Concentrations in epithelium and stroma were com-
bined to simulate volume-averaged concentrations in biopsies,
as would be obtained in a PK study [14]. We computed values
of Cmax and C24 for biopsy and blood compartments for direct
comparisons with the PK data (median values given in Table 3
of reference [27]). Relative differences are given in Table 4.
The differences between theory and experiment in Table 4
are very small compared to the variability in the PK data. We
posit that the agreement between theory and experiment here
is sufficiently good to motivate further applications of the
model.
Protective effect of TFV-DP
Computations here used an EC50 as a target concentration for
computations of a measure of potential for HIV prophylaxis
(the percent protected). A more conservative approach would
be to use an EC90 value. However, because we evaluated a 2
log range of the EC50 value, we believe that computations
here demonstrate the potential value of this approach in help-
ing understand and quantify the conditions of prophylaxis. In
particular, we found that increasing the target prophylactic
TFV-DP concentration slows the post-gel insertion rise to
the maximum potential for protection, but does not apprecia-
bly alter that level over 24 h. As seen in Fig. 7, the spatial
average concentration of tenofovir diphosphate in the stroma
rises rapidly with respect to the minimum threshold EC50
value, surpassing this at a time small compared to the effective
tbend for percent protected (Fig. 8). This is because percent
protected is limited by how rapidly and completely the gel
coats the length of the canal. Regions of mucosa not coated
by gel have very little drug in them for extended times (be-
cause longitudinal drug diffusion in the tissue is very slow).
As noted above, there are relatively high TFV-DP concentra-
tions in the upper stroma, but these drop off rapidly with depth
below. Thus, the lower regions of the stroma have very low
TFV-DP concentrations at earlier times and this, as well as the
finite rate of gel spreading, drives down the net volume of
stromal tissue with protective TFV-DP levels at those times.
Intromission likely smoothes out gel distribution and may
extend completeness of coating along the canal. However,
subsequent semen deposition may rapidly expose tissue to
virus to the extent that uncoated, bare regions of the epithelial
surfaces remain. Thus, in those regions, drug has little oppor-
tunity to diffuse into/through tissue prior to arrival of the vi-
rions. In contrast, in coated regions, the relatively slow HIV
migration through the epithelium and past the upper few hun-
dred mirometers of the stroma allows more time for protective
TFV-DP to diffuse lower into the stroma. Overall, the percent
protected measure captures the preponderance of how the
time-space history of TFV-DP may neutralize HIV infection
of stromal host cells, but not its entirety. Mathematically
speaking, a bivariate characterization of both TFV-DP con-
centration distribution and the degree of gel coating might
provide a more complete measure of protection.
Summary
A general compartmental PK model was developed and ap-
plied to human vaginal delivery of tenofovir by a gel. The
approach is fundamentally applicable to the range of microbi-
cide drugs being evaluated. Multiple factors interact in non-
linear ways to govern tenofovir delivery, production of
tenofovir diphosphate, and the protective effect of the
tenofovir diphosphate. The model here defines and integrates
them in a deterministic way.
Results show that predictions of gel spreading per se in-
form us significantly about tenofovir delivery and consequent
protection by tenofovir diphosphate, as well as about propen-
sity for gel leakage. The new measure of protection, termed
percent protected, provides for the first time an objective,
mechanism-based metric that can be computed to assist in
product design and evaluation. The time dependence of per-
cent protected provides insights about the time, post-gel inser-
tion, required to achieve maximal protection, the degree of
that protection, and its duration (akin to classical pharmaco-
logical analysis of drug concentrations). Analysis using the
percent protected metric here is striking in that it suggests that
the low viscosity, runny gel would—despite it propensity for
Table 4 Differences between predictions of model for the clinical 1 %
tenofovir gel applied at the fornix in a 4-mL volume to a vagina of
average dimensions vs. human PK data [27]
Cmax (%) C24 (%)
Biopsy −5.5 12.2
Blood 19.4 −2.4
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leakage and even with a smaller loaded drug mass—deliver
more tenofovir initially and would as rapidly create prophy-
lactic concentration distributions of tenofovir diphosphate as
would a Btypical^ microbicide gel of intermediate viscosity
(that even packages more drug). This is because thinner gel
coating layers engender faster diffusion of drug into the epi-
thelium than thicker ones. The implication is, for example,
that a small volume of a microbicide gel that spreads well to
effectively coat the vaginal canal and for which retention is
promoted by properties such as bioadhesiveness (not included
here, but addressable in this type of modeling) to inhibit leak-
age might be an alternative to the high volume microbicide
gels previously evaluated in clinical trials. Overall, the new
modeling approach here extends earlier efforts to create com-
putational tools that can be used in the objective prospective
design of new, improved microbicide products and in the ret-
rospective design of existing ones.
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